Histone deacetylase 3 controls a transcriptional network required for B cell maturation

Histone deacetylase 3 (Hdac3) is a target of the FDA approved HDAC inhibitors, which are used for the treatment of lymphoid malignancies. Here, we used Cd19-Cre to conditionally delete Hdac3 to define its role in germinal center B cells, which represent the cell of origin for many B cell malignancie...

Descripción completa

Detalles Bibliográficos
Autores principales: Stengel, Kristy R, Bhaskara, Srividya, Wang, Jing, Liu, Qi, Ellis, Jacob D, Sampathi, Shilpa, Hiebert, Scott W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Gene regulation, Chromatin and Epigenetics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6847391/
https://www.ncbi.nlm.nih.gov/pubmed/31586401
http://dx.doi.org/10.1093/nar/gkz816

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6847391/
https://www.ncbi.nlm.nih.gov/pubmed/31586401
http://dx.doi.org/10.1093/nar/gkz816

Ejemplares similares